Clinical Trial Detail

NCT ID NCT02977780
Title INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

gliosarcoma

glioblastoma multiforme

Therapies

CC-115

Abemaciclib + Temozolomide

Temozolomide

Neratinib + Temozolomide

Age Groups: adult senior

Additional content available in CKB BOOST